Actinium Pharmaceuticals Grants Equity Awards to New CFO, Business Development Chief
Actinium Pharmaceuticals granted CFO Matt David a non-qualified stock option covering 250,000 shares on October 14, 2026, exercisable at $0.97 per share. David also received 250,000 restricted stock units vesting over three years, with up to 75,000 additional units tied to corporate milestones. Senior Vice President, B